Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX005N in Adult Prurigo Nodularis – Long-term Safety and Efficacy Extension
CTR20232108Phase 2Completed
- Sponsor
- Qyuns Therapeutics
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QX005N in prurigo nodularis (PN), sponsored by Qyuns Therapeutics. Started Jul 2023; status: completed.
02
Drugs
QX005N
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on CTR20232108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232108.